Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Zacks Investment Research Inc.
$12.00
Provider: Zacks Investment Research Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sunshine Heart Inc Announces Conditional Approval Of IDE From FDA for C-Pulse Heart Assist System


Monday, 1 Oct 2012 05:15am EDT 

Sunshine Heart Inc announced that it has received conditional approval from the FDA for an Investigational Device Exemption (IDE) for its flagship C-Pulse Heart Assist System. 

Company Quote

5.64
-0.47 -7.69%
19 Sep 2014